MEDFORD, N.Y.--(BUSINESS WIRE)--Chembio Diagnostics Inc. (OTCBB: CEMI) has received CLIA Waiver for one of its two FDA-approved rapid HIV tests, HIV 1/2 STAT-PAK™. The CLIA (Clinical Laboratory Improvement Act) waiver allows Chembio to market these HIV tests to a potential market of approximately 189,000 laboratory entities across the United States, including doctors’ offices and clinics.
